Notably, the use of Selpercatinib in patients with RET fusion-positive NSCLC who have undergone platinum-based chemotherapy or remained untreated resulted in a significant reduction in tumor growth with minimal toxicity [166]. Here, RET is linked to non-small cell lung carcinoma.